Convulsions

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider for any medical condition or before making any decisions about your health or treatment. Clinical judgment is paramount in all patient care decisions.

---

Overview

• Definition: A convulsion refers specifically to the paroxysmal, involuntary muscle contractions and relaxations (jerking) that characterize many types of seizures, particularly generalized tonic-clonic seizures. More broadly, a seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Epilepsy is a disease characterized by an enduring predisposition to generate epileptic seizures and by the neurobiologic, cognitive, psychological, and social consequences of this condition. A diagnosis of epilepsy requires at least two unprovoked (or reflex) seizures >24 hours apart, or one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years, or diagnosis of an epilepsy syndrome.
• Epidemiology:
  • Incidence of first unprovoked seizure: Approximately 40-70 per 100,000 person-years, with a bimodal distribution (highest in early childhood and in the elderly).
  • Prevalence of epilepsy: Approximately 1% of the global population, affecting around 50-70 million people worldwide.
  • Demographics: Can affect individuals of any age, gender, or ethnicity. Age-specific causes are important (e.g., febrile seizures in children, cerebrovascular disease in the elderly).
• Classification: The International League Against Epilepsy (ILAE) 2017 classification categorizes seizures based on onset:
  • Focal onset: Originate in one hemisphere.
    • Focal aware (consciousness preserved)
    • Focal impaired awareness (consciousness impaired)
    • Focal to bilateral tonic-clonic (formerly secondary generalization)
  • Generalized onset: Originate at some point within, and rapidly engage, bilaterally distributed networks.
    • Motor (e.g., tonic-clonic, tonic, clonic, myoclonic, atonic)
    • Non-motor (e.g., absence)
  • Unknown onset: When the onset is not observed or cannot be determined. May be reclassified once more information is obtained.
  • Convulsions primarily refer to the motor manifestations, most commonly seen in generalized tonic-clonic seizures, but also in focal seizures that become secondarily generalized or certain generalized motor seizures (tonic, clonic, myoclonic).

Pathophysiology

• Mechanism: Seizures result from a sudden, transient disruption of brain function due to abnormal, hypersynchronous electrical discharge of cortical neurons. This involves:
  • Excitatory-Inhibitory Imbalance: An imbalance between excitatory (e.g., glutamate, aspartate) and inhibitory (e.g., GABA) neurotransmission, favoring excitation.
  • Neuronal Hyperexcitability: Individual neurons become hyperexcitable due to changes in ion channel function (e.g., voltage-gated sodium or calcium channels, potassium channels), receptor alterations, or impaired glial buffering of extracellular ions/neurotransmitters.
  • Network Synchronization: Hyperexcitable neurons recruit neighboring neurons into a synchronized discharge, forming a "seizure focus" or rapidly engaging widespread networks. This can involve both cortical and subcortical structures.
  • Tonic-Clonic Phases:
    • Tonic phase: High-frequency, low-amplitude discharges spread rapidly, leading to sustained muscle contraction due to widespread neuronal depolarization.
    • Clonic phase: Intermittent neuronal inhibition superimposed on excitation leads to rhythmic muscle jerking.
• Risk Factors:
  • Genetic Predisposition: Specific genetic mutations (e.g., in ion channel genes) or family history of epilepsy.
  • Structural Brain Lesions: Stroke (ischemic or hemorrhagic), brain tumors, head trauma (especially severe penetrating injuries), congenital brain malformations, arteriovenous malformations, cortical dysplasia, hippocampal sclerosis.
  • Infections: Meningitis, encephalitis, brain abscess, neurocysticercosis, HIV-related encephalopathy.
  • Metabolic Derangements: Hypoglycemia, hyponatremia, hypocalcemia, hypomagnesemia, uremia, hepatic encephalopathy, porphyria.
  • Substance-related: Alcohol withdrawal, benzodiazepine withdrawal, stimulant use (e.g., cocaine, amphetamines), certain drug intoxications (e.g., tramadol, bupropion, high-dose penicillin).
  • Autoimmune/Inflammatory Conditions: Autoimmune encephalitis (e.g., anti-NMDAR encephalitis), systemic lupus erythematosus, multiple sclerosis.
  • Perinatal Injury: Hypoxic-ischemic encephalopathy, intracranial hemorrhage.
  • Fever: Febrile seizures in children (typically benign, age 6 months to 5 years).
  • Sleep Deprivation: A common precipitant for seizures in individuals with epilepsy.
  • Other: Eclampsia in pregnancy, cerebral anoxia.
• Protective Factors:
  • Primary Prevention: General measures to reduce risk factors for brain injury: helmet use, stroke prevention (blood pressure control, diabetes management), vaccination against infectious diseases (e.g., meningitis), avoidance of illicit drug use, appropriate management of metabolic disorders.
  • Secondary Prevention: For individuals with epilepsy, consistent adherence to antiepileptic drug (AED) regimens, identifying and avoiding personal seizure triggers (e.g., sleep deprivation, alcohol, flashing lights), and stress management.

Clinical Presentation

Signs and Symptoms

• Cardinal Features (Generalized Tonic-Clonic Seizure - GTCS):
  • Prodrome (pre-seizure): May occur hours or days before, non-specific (e.g., mood changes, headache, lethargy).
  • Aura (focal onset evolving to GTCS): A focal seizure that precedes and heralds a generalized seizure, e.g., strange smell, déja vu, tingling, rising epigastric sensation.
  • Tonic Phase (10-30 seconds): Sudden loss of consciousness, stiffening of all limbs and back, jaw clenching, upward eye deviation. May include a "epileptic cry" as air is forced past vocal cords. Apnea and cyanosis may occur.
  • Clonic Phase (30-60 seconds, can be longer): Rhythmic, bilateral jerking of the extremities, often slowing in frequency towards the end. Tongue biting (lateral) and urinary/fecal incontinence are common.
  • Postictal Phase (minutes to hours): Flaccidity, deep breathing (postictal hyperventilation), confusion, drowsiness, headache, muscle soreness (myalgia), often amnestic for the event.
• Early Signs:
  • Subtle changes in behavior or consciousness (e.g., staring, automatisms in focal impaired awareness seizures).
  • Localized twitching or sensory phenomena in focal aware seizures.
• Advanced Signs:
  • Significant injuries (head trauma, fractures, burns) due to falls during seizures.
  • Prolonged postictal confusion or focal neurological deficit (Todd's paralysis), suggesting a focal onset.
  • Status epilepticus (seizure lasting >5 minutes or recurrent seizures without full recovery of consciousness between them).
• Atypical Presentations:
  • Absence Seizures: Brief (5-10 seconds) staring spells, unresponsiveness, subtle automatisms, no postictal confusion. Predominantly in children.
  • Myoclonic Seizures: Sudden, brief, shock-like jerks of a muscle or group of muscles.
  • Atonic Seizures: Sudden loss of muscle tone, causing falls ("drop attacks").
  • Non-Epileptic Seizures (NES) / Psychogenic Non-Epileptic Seizures (PNES): Events resembling epileptic seizures but without abnormal electrical brain activity. Often variable, asynchronous, prolonged, preserved consciousness despite unresponsiveness, resistance to passive eye opening, no typical postictal state (or rapid recovery). Triggered by stress or emotional factors.
  • Syncope: Brief loss of consciousness due to transient cerebral hypoperfusion, often preceded by presyncope (lightheadedness, visual changes), triggered by specific situations (e.g., standing, pain), rapid recovery. Brief, mild tonic or clonic movements can occur (convulsive syncope).

Physical Examination

• Inspection:
  • During Seizure: Observe motor activity (tonic, clonic, automatisms), eye movements, head deviation, presence of cyanosis, salivation, tongue biting, incontinence. Time the seizure.
  • Postictally: Level of consciousness, signs of injury (tongue lacerations, head trauma, shoulder dislocation), skin color (pale, flushed), presence of rashes (e.g., neurocutaneous stigmata like café-au-lait spots, ash leaf spots).
• Palpation:
  • Postictally: Tenderness over muscles (myalgia), palpate for fractures or dislocations if injury suspected.
• Special Tests:
  • Neurological Examination (Postictally): Assess mental status, cranial nerves, motor and sensory function, reflexes. Transient focal weakness (Todd's paralysis) can indicate focal seizure onset. Persistence of focal deficits warrants urgent investigation.
  • Vital Signs: Tachycardia and hypertension are common during seizures. Postictally, vital signs often normalize, but may reflect underlying conditions.
  • Fundoscopy: Check for signs of increased intracranial pressure (papilledema), which might suggest a mass lesion.

Diagnostic Approach

History Taking

• Key Questions:
  • Description of Event: Crucial to obtain from a witness. What happened before, during, and after the event? Sequence of events, presence of aura, motor manifestations (symmetry, type of jerking), duration, incontinence, tongue biting, eye deviation, changes in breathing/color.
  • Postictal State: Duration and nature of confusion, drowsiness, speech difficulties, focal weakness, headache, muscle soreness.
  • Provoking Factors: Sleep deprivation, alcohol/drug use/withdrawal, fever, stress, flashing lights, medication non-adherence.
  • Past Medical History: Previous seizures, head trauma, stroke, meningitis/encephalitis, brain surgery, family history of epilepsy, psychiatric history.
  • Medications: Current medications (including over-the-counter and herbal supplements), recent changes, adherence to AEDs.
  • Comorbidities: Diabetes, heart disease, kidney/liver disease.
  • Pregnancy Status: For women of childbearing age.
• Red Flags:
  • First seizure in an adult.
  • Focal neurological deficit (during or after seizure).
  • Prolonged seizure (status epilepticus).
  • Slow or incomplete recovery from postictal state.
  • Associated fever, severe headache, neck stiffness (suggesting infection).
  • Signs of head trauma.
  • New focal findings on neurological exam.
  • Recurrent seizures without regaining full consciousness.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): To evaluate for infection, anemia.
  • Electrolytes (Na, K, Ca, Mg): To identify metabolic causes (e.g., hyponatremia, hypocalcemia).
  • Glucose: To rule out hypoglycemia or hyperglycemia.
  • Renal and Hepatic Function Tests: To assess organ dysfunction that could precipitate seizures or affect AED metabolism.
  • Toxicology Screen (Urine/Blood): To detect illicit drugs or toxins (e.g., cocaine, amphetamines, tricyclic antidepressants).
  • Serum Prolactin: Often significantly elevated 10-20 minutes post-generalized tonic-clonic seizure, differentiating it from psychogenic non-epileptic seizures or syncope (less reliable for focal seizures). Levels peak at 15-30 minutes and normalize within 60 minutes.
  • Antiepileptic Drug (AED) Levels: If the patient is already on AEDs, to check for subtherapeutic levels or toxicity.
• Confirmatory:
  • Lumbar Puncture (CSF Analysis): If infection (meningitis, encephalitis) or autoimmune etiology is suspected (fever, neck stiffness, altered mental status, immunocompromise).
  • Genetic Testing: For specific epilepsy syndromes, especially in children or when a genetic cause is suspected (e.g., Dravet syndrome, SCN1A mutations).
  • Autoantibody Panel: If autoimmune encephalitis is suspected (e.g., anti-NMDAR, anti-LGI1, anti-GABABR).
• Monitoring:
  • AED Levels: Periodically to ensure therapeutic range, especially with dosage adjustments, drug interactions, or suspicion of non-adherence/toxicity. Not always necessary if patient is seizure-free and tolerating medication well.
  • CBC, LFTs, Renal Function: Periodically, especially with certain AEDs known for hematologic or hepatic side effects (e.g., carbamazepine, valproate, phenytoin).

Imaging

• Recommended:
  • Magnetic Resonance Imaging (MRI) Brain with Epilepsy Protocol: Preferred neuroimaging modality for evaluating new-onset unprovoked seizures, particularly when structural lesions are suspected. It offers superior resolution for detecting subtle abnormalities like hippocampal sclerosis, cortical dysplasia, tumors, and vascular malformations. Should be done promptly after a first seizure unless a clear reversible cause is identified.
  • Computed Tomography (CT) Brain: More readily available, quicker, and useful in acute emergency settings to rule out acute intracranial pathology such as hemorrhage, large tumors, or hydrocephalus, especially in patients with acute neurological changes or head trauma. Less sensitive for subtle lesions than MRI.
• Advanced:
  • Functional MRI (fMRI): Used to localize eloquent cortex (e.g., language, motor areas) prior to epilepsy surgery.
  • Positron Emission Tomography (PET): Often using 18F-FDG, can identify areas of hypometabolism in the brain which may correspond to an epileptic focus in refractory epilepsy.
  • Single-Photon Emission Computed Tomography (SPECT): Can measure cerebral blood flow, typically performed interictally (showing hypoperfusion) and ictally (showing hyperperfusion in the seizure onset zone). Used in presurgical evaluation.
  • Magnetoencephalography (MEG): Non-invasive technique to detect and localize interictal epileptiform discharges with high spatial resolution, useful for surgical planning.

Management

Acute Management (Status Epilepticus or Acute Symptomatic Seizure)

• Immediate (First 0-5 minutes):
  • Protect from Injury: Move objects away, cushion head, loosen tight clothing. DO NOT restrain the patient or place anything in their mouth.
  • Time the Seizure: Crucial for determining status epilepticus.
  • Assess Airway, Breathing, Circulation (ABCs): Position patient on their side to prevent aspiration. Administer oxygen.
  • Establish IV Access: If possible.
  • Check Glucose: Rapid fingerstick glucose to rule out hypoglycemia.
• Stabilization (First 5-20 minutes - Initial Therapy for Status Epilepticus):
  • First-Line Pharmacological Intervention: Benzodiazepines are the cornerstone.
    • Lorazepam: IV 0.1 mg/kg (up to 4 mg) at 2 mg/min, may repeat once after 5-10 minutes. Preferred IV due to rapid onset and longer duration.
    • Midazolam: IM 10 mg for adults (5 mg if >65 years), or buccal/intranasal 0.2 mg/kg (max 10 mg). Useful in pre-hospital settings or without IV access.
    • Diazepam: IV 0.15-0.2 mg/kg (up to 10 mg) at 5 mg/min, may repeat once. Rectal gel 0.2 mg/kg (max 20 mg). Faster onset but shorter duration than lorazepam.
  • Identify and Treat Reversible Causes: Administer 50% dextrose (50 mL IV) if hypoglycemia is present or suspected. Thiamine (100 mg IV) should precede dextrose in patients with suspected alcohol misuse or malnutrition.
• Emergency (20-40 minutes - Second-Line Therapy for Refractory Status Epilepticus):
  • If seizures persist despite benzodiazepines, load with a non-benzodiazepine antiepileptic drug:
    • Fosphenytoin: IV 20 mg PE/kg (phenytoin equivalents) at 150 mg PE/min. Less risk of infusion site reactions than phenytoin. (Max 1500 mg PE).
    • Phenytoin: IV 20 mg/kg at 50 mg/min. (Max 1500 mg). Requires cardiac monitoring due to risk of hypotension and arrhythmias.
    • Levetiracetam: IV 20-60 mg/kg (initial dose usually 1000-1500 mg) over 15 minutes. High safety profile, broad spectrum.
    • Valproate Sodium: IV 20-40 mg/kg at 6 mg/kg/min (initial dose usually 1000 mg) over 15-30 minutes. (Max 3000 mg).
  • Refractory Status Epilepticus (>40 minutes):
    • Consider continuous EEG monitoring.
    • Intubation and mechanical ventilation may be required for airway protection.
    • Initiate continuous IV infusions of anesthetic agents:
      • Midazolam: IV loading dose 0.2 mg/kg, then infusion 0.05-0.4 mg/kg/hr.
      • Propofol: IV loading dose 1-2 mg/kg, then infusion 20-200 mcg/kg/min.
      • Pentobarbital: IV loading dose 5-15 mg/kg, then infusion 0.5-5 mg/kg/hr.
    • Aim for burst suppression on EEG.

Chronic Management (Epilepsy)

• Pharmacological: Antiepileptic Drugs (AEDs) are the mainstay.
  • Principles: Monotherapy is preferred. Start low, titrate slow. Goal is seizure freedom with minimal side effects. Choice depends on seizure type, epilepsy syndrome, side effect profile, comorbidities, age, and potential drug interactions.
  • First-Line Options (examples):
    • Generalized Tonic-Clonic Seizures: Levetiracetam, Lamotrigine, Valproate (caution in women of childbearing potential due to teratogenicity), Topiramate.
    • Focal Seizures: Levetiracetam, Lamotrigine, Carbamazepine, Oxcarbazepine.
    • Absence Seizures: Ethosuximide (pure absence), Valproate, Lamotrigine.
    • Myoclonic Seizures: Valproate, Levetiracetam, Clonazepam.
  • Specific Drug Considerations:
    • Levetiracetam (Keppra): Broad-spectrum, generally well-tolerated. Side effects: irritability, behavioral changes, somnolence. Dosage: typically 500-1500 mg BID.
    • Lamotrigine (Lamictal): Broad-spectrum, good for generalized and focal seizures. Side effects: rash (Stevens-Johnson syndrome, particularly with rapid titration), insomnia, dizziness. Dosage: slow titration (e.g., 25 mg/day for 2 weeks) to target 100-400 mg/day in 1-2 doses.
    • Valproate (Depakote): Broad-spectrum, very effective for generalized seizures. Side effects: weight gain, hair loss, tremor, hepatotoxicity, pancreatitis, teratogenicity (neural tube defects). Dosage: 500-2500 mg/day in 1-3 doses.
    • Carbamazepine (Tegretol): Effective for focal seizures. Side effects: hyponatremia, rash (SJS/TEN in HLA-B*1502 allele, common in Asian descent), bone marrow suppression. Dosage: 400-1200 mg/day in 2-3 doses.
    • Oxcarbazepine (Trileptal): Similar to carbamazepine but lower risk of rash and bone marrow effects, higher risk of hyponatremia. Effective for focal seizures. Dosage: 600-2400 mg/day in 2 doses.
    • Topiramate (Topamax): Broad-spectrum. Side effects: cognitive slowing ("dopey-max"), weight loss, paresthesias, kidney stones, acute angle-closure glaucoma. Dosage: 100-400 mg/day in 2 doses.
• Non-pharmacological:
  • Epilepsy Surgery: For refractory focal epilepsy, especially when a resectable lesion (e.g., hippocampal sclerosis, tumor, cortical dysplasia) can be identified. Presurgical evaluation includes advanced imaging, continuous video-EEG monitoring, and sometimes intracranial EEG.
  • Vagus Nerve Stimulation (VNS): Implantable device that delivers intermittent electrical stimulation to the left vagus nerve, used for drug-resistant focal or generalized epilepsy.
  • Responsive Neurostimulation (RNS): Device implanted intracranially that detects abnormal brain activity and delivers short bursts of electrical stimulation to interrupt seizures. For drug-resistant focal epilepsy.
  • Deep Brain Stimulation (DBS): Bilateral stimulation of the anterior nucleus of the thalamus is approved for drug-resistant focal epilepsy.
  • Ketogenic Diet: High-fat, low-carbohydrate, adequate-protein diet that induces a state of ketosis. Primarily used in children with refractory epilepsy, but also sometimes in adults.
  • Lifestyle Modifications: Regular sleep patterns, stress management, avoidance of known triggers (e.g., alcohol, excessive caffeine, illicit drugs), adherence to medication.
• Monitoring:
  • Seizure Diary: To track seizure frequency, type, duration, and potential triggers. Essential for assessing treatment efficacy.
  • Adverse Effects: Regular assessment of AED side effects through patient interviews, physical exam, and targeted lab tests (e.g., LFTs, CBC, electrolytes) for specific AEDs.
  • AED Blood Levels: Routinely monitored for drugs with narrow therapeutic indices (e.g., phenytoin, carbamazepine), when clinical response is inadequate, suspecting toxicity, or monitoring adherence. Not routinely required for newer AEDs like levetiracetam or lamotrigine if seizure-free and well-tolerated.
  • Quality of Life: Assess impact of epilepsy and its treatment on patient's daily life, mood, cognition, and social functioning.

Treatment Algorithms

• First-Line (New-onset Epilepsy):
  1. Confirm diagnosis of epilepsy (not acute symptomatic seizure or mimic).
  2. Determine seizure type/epilepsy syndrome using history, EEG, and MRI.
  3. Choose appropriate AED based on seizure type, patient comorbidities, potential side effects, and individual factors (e.g., age, gender, pregnancy potential).
  4. Start with monotherapy, low dose, titrate slowly to effective dose or until side effects limit further increase.
  5. Educate patient on medication adherence, common side effects, and seizure precautions.
• Second-Line (After Failure of First AED):
  1. Confirm adherence and therapeutic dosing of the first AED.
  2. If first AED failed due to lack of efficacy at maximal tolerated dose: Switch to an alternative first-line AED for that seizure type, usually by slowly tapering off the first drug while titrating on the second.
  3. If first AED failed due to intolerable side effects: Switch to an alternative first-line AED.
  4. Consider combination therapy (adding a second AED) if monotherapy fails after trying two appropriate AEDs, particularly if different mechanisms of action.
• Refractory Cases (Drug-Resistant Epilepsy): Defined as failure of adequate trials of two tolerated, appropriately chosen and used AED regimens (as monotherapy or in combination) to achieve sustained seizure freedom.
  1. Re-evaluate Diagnosis: Confirm it is truly epilepsy and not a mimic (especially PNES). Re-evaluate seizure type/syndrome.
  2. Refer to Comprehensive Epilepsy Center: For specialized evaluation and management.
  3. Advanced Diagnostics: Prolonged video-EEG monitoring, high-resolution MRI, PET, SPECT, MEG to localize seizure focus.
  4. Consider Non-pharmacological Therapies: Epilepsy surgery (if resectable focus), VNS, RNS, DBS, ketogenic diet.
  5. Newer AEDs: Explore newer AEDs or combinations.

Complications

• Common:
  • Injuries: Lacerations (especially tongue), bruising, fractures, dislocations (e.g., posterior shoulder dislocation), head trauma due to falls during seizures.
  • Postictal Morbidity: Prolonged confusion, headache, fatigue, myalgia, temporary focal deficits (Todd's paralysis).
  • Psychosocial Impact: Anxiety, depression, social stigma, driving restrictions, employment difficulties.
  • Aspiration: During or immediately after seizures due to impaired consciousness.
• Serious:
  • Status Epilepticus: Medical emergency, prolonged or continuous seizure activity leading to neuronal damage, systemic complications (hypoxia, acidosis, hyperthermia, rhabdomyolysis, renal failure). High morbidity and mortality.
  • Sudden Unexpected Death in Epilepsy (SUDEP): Leading direct cause of death in people with refractory epilepsy. Exact mechanism unknown, but likely involves respiratory depression, cardiac arrhythmia, or autonomic dysfunction post-seizure. Risk factors include frequent GTCS, early age of epilepsy onset, and non-adherence to AEDs.
  • Aspiration Pneumonia: From aspiration of gastric contents.
  • Rhabdomyolysis: Severe muscle breakdown due to intense muscle contractions during prolonged seizures, leading to acute kidney injury.
• Long-term:
  • Cognitive Impairment: Memory problems, executive dysfunction, attentional deficits, especially with frequent seizures or certain AEDs.
  • Psychiatric Comorbidity: High prevalence of depression, anxiety, psychosis.
  • Medication Side Effects: Chronic issues (e.g., osteoporosis with enzyme-inducing AEDs, weight changes, cosmetic effects).
  • Social Isolation: Due to stigma, driving restrictions, and fear of seizures.

Prognosis

• Factors:
  • Epilepsy Syndrome/Etiology: Idiopathic/genetic epilepsies often have better prognosis (e.g., juvenile myoclonic epilepsy responds well to valproate) than symptomatic/structural epilepsies.
  • Seizure Type: Generalized tonic-clonic seizures may have higher risk of SUDEP. Absence epilepsy in children often remits.
  • Response to AEDs: Approximately 60-70% of people with new-onset epilepsy achieve seizure freedom with the first or second AED. About 30% have drug-resistant epilepsy.
  • Age of Onset: Generally better prognosis if epilepsy starts in childhood than in adulthood (where it's more often symptomatic).
  • Frequency and Severity of Seizures: More frequent or severe seizures are associated with poorer outcomes.
  • Comorbidities: Presence of other neurological or psychiatric conditions can worsen prognosis.
• Survival: Overall mortality rates are higher in individuals with epilepsy compared to the general population, largely due to SUDEP, accidents, and underlying neurological conditions. However, with effective management, most individuals live a normal lifespan.
• Quality of Life: Can be significantly impacted by seizure frequency, side effects of AEDs, fear of seizures, driving restrictions, employment discrimination, and psychiatric comorbidities. Comprehensive care addressing these aspects is crucial.

Prevention

• Primary: Aimed at preventing the development of epilepsy or first seizures.
  • Injury Prevention: Use of helmets to prevent head trauma, which is a significant risk factor for post-traumatic epilepsy.
  • Stroke Prevention: Management of cardiovascular risk factors (hypertension, diabetes, dyslipidemia) to reduce incidence of stroke, a major cause of acquired epilepsy in adults.
  • Infection Control: Vaccination against diseases that can cause brain infections (e.g., meningitis, measles, mumps). Prompt treatment of CNS infections.
  • Perinatal Care: Improved obstetric care to reduce birth trauma and hypoxic-ischemic injury.
  • Avoidance of Toxins: Discouraging illicit drug use and counseling on judicious use of medications with seizure-inducing potential.
• Secondary: Early detection and intervention to prevent seizure recurrence or progression of epilepsy.
  • First Unprovoked Seizure Management: Decision to start AEDs after a first unprovoked seizure is individualized, balancing recurrence risk (estimated 30-50% after one unprovoked seizure, higher with epileptiform EEG or structural lesion) against potential AED side effects. Often, AEDs are initiated if recurrence risk is high (>60%).
  • Optimal AED Therapy: Adherence to prescribed AEDs, appropriate dosing, and regular follow-up to achieve seizure freedom.
  • Trigger Avoidance: Identifying and avoiding personal seizure triggers (e.g., sleep deprivation, excessive alcohol, stress, specific sensory stimuli).
• Tertiary: Preventing complications and improving outcomes in established epilepsy.
  • Seizure Action Plans: For individuals and caregivers, detailing what to do during a seizure and when to seek emergency care.
  • Risk Reduction for SUDEP: Counseling patients on SUDEP risks, encouraging medication adherence, and potentially exploring nocturnal monitoring devices.
  • Comorbidity Management: Proactive screening and management of psychiatric comorbidities (depression, anxiety), cognitive issues, and bone health.
  • Lifestyle Counseling: Promoting healthy lifestyle, including regular sleep, balanced diet, and moderate exercise.

Special Populations

• Pediatric:
  • Febrile Seizures: Common (2-5% of children aged 6 months to 5 years). Usually benign, generalized, short-lived, with normal development. Recurrence risk 30-40%. Management is generally supportive; long-term AEDs not usually indicated for simple febrile seizures.
  • Specific Epilepsy Syndromes: Many syndromes are unique to childhood (e.g., infantile spasms, Lennox-Gastaut syndrome, Dravet syndrome, benign rolandic epilepsy). Diagnosis and treatment are syndrome-specific.
  • AED Dosing: Based on weight. Pharmacokinetics differ in children. Side effect profiles can also vary (e.g., behavioral issues with levetiracetam more common).
  • Developmental Impact: Monitor for developmental delay or regression.
• Geriatric:
  • Higher Incidence of New-Onset Epilepsy: Primarily due to acquired causes like stroke, neurodegenerative diseases (e.g., Alzheimer's disease), brain tumors, and head trauma.
  • Polypharmacy and Drug Interactions: Increased risk of adverse effects and interactions with other medications.
  • AED Selection: Tend to prefer AEDs with fewer cognitive side effects and favorable pharmacokinetic profiles (e.g., lamotrigine, levetiracetam, gabapentin). Start with lower doses and titrate slowly. Avoid AEDs with significant sedation or cardiac effects (e.g., phenytoin, carbamazepine in some cases).
  • Comorbidities: Higher prevalence of renal/hepatic impairment, cardiovascular disease, osteoporosis, and cognitive decline influence AED choice and monitoring.
  • Seizure Presentation: May be more subtle or non-convulsive.
• Pregnancy:
  • Folic Acid Supplementation: All women of childbearing potential on AEDs should take high-dose folic acid (4 mg/day) at least 3 months prior to conception and through the first trimester to reduce risk of neural tube defects.
  • Teratogenicity: Some AEDs carry higher teratogenic risks (e.g., valproate highest, especially for neural tube defects and developmental delay; carbamazepine, phenytoin). Lower-risk AEDs include lamotrigine and levetiracetam.
  • Seizure Control: Maintaining seizure freedom is crucial for maternal and fetal health. Risk of status epilepticus is higher in pregnant women with poor seizure control.
  • AED Levels: Plasma concentrations of some AEDs (e.g., lamotrigine, levetiracetam) can decrease significantly during pregnancy due to increased metabolism and volume of distribution, requiring dose adjustments.
  • Breastfeeding: Most AEDs are excreted into breast milk but generally in low enough concentrations to be safe. Discuss with clinician.
• Comorbidities:
  • Renal/Hepatic Impairment: Requires dose adjustment for many AEDs (e.g., gabapentin, pregabalin, levetiracetam renally excreted; valproate, phenytoin, carbamazepine hepatically metabolized).
  • Psychiatric Disorders: High co-occurrence of depression, anxiety. Choose AEDs with favorable psychotropic effects or minimal psychiatric side effects (e.g., lamotrigine for mood stabilization, avoid topiramate or levetiracetam if history of severe mood issues).
  • Cardiac Disease: Avoid AEDs that can affect cardiac conduction (e.g., carbamazepine, phenytoin).
  • Bone Health: Enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital) can increase risk of osteoporosis; monitor bone density and supplement with vitamin D and calcium.

Clinical Pearls

• Diagnostic:
  • Witness History is Gold: The description from a reliable witness is often the most critical piece of information for differentiating a seizure from mimics.
  • Prolactin Levels: A postictal serum prolactin level drawn 10-30 minutes after a suspected generalized tonic-clonic seizure can help distinguish it from psychogenic non-epileptic seizures or syncope, though not definitive.
  • Mimics: Always consider syncope (often situational, prodrome, rapid recovery), psychogenic non-epileptic seizures (variable, asynchronous, prolonged, no typical postictal state, often resistant to sedatives), TIA, migraine with aura, movement disorders, sleep disorders.
  • EEG Limitations: A normal interictal EEG does not rule out epilepsy, and an abnormal EEG does not necessarily confirm it (e.g., epileptiform activity in asymptomatic individuals).
• Treatment:
  • "Start Low, Go Slow": Titrate AEDs gradually to minimize side effects and improve tolerability.
  • Monotherapy Goal: Aim for seizure freedom on a single AED. Polytherapy increases side effects and drug interactions.
  • Never Abruptly Stop AEDs: Abrupt withdrawal can precipitate status epilepticus or increase seizure frequency. Always taper slowly under medical supervision.
  • Patient Education: Crucial for adherence, trigger avoidance, and understanding side effects.
  • Driving Restrictions: Advise patients on local driving regulations for epilepsy (often 6-12 months seizure-free period).
• Pitfalls:
  • Misdiagnosis of PNES: Leading to inappropriate and potentially harmful AED treatment. Video-EEG monitoring is the gold standard for diagnosis.
  • Underestimation of SUDEP Risk: Important to discuss with patients and families, especially those with refractory GTCS.
  • Ignoring Psychosocial Aspects: Epilepsy significantly impacts quality of life, mental health, and social functioning. Holistic care is essential.
  • Over-reliance on AED Levels: Clinical response and tolerability should guide dosing, not solely AED blood levels (except for drugs with narrow therapeutic windows or suspected toxicity/non-adherence).

Recent Updates

• Guidelines:
  • ILAE Classification (2017): Emphasizes seizure onset (focal, generalized, unknown) and descriptive terminology, improving clarity and guiding treatment selection.
  • NICE Guidelines (UK): Regular updates on diagnosis and management of epilepsy, including first seizures, status epilepticus, and specific populations.
  • AAN Guidelines (US): Practice guidelines on various aspects of epilepsy, including initiating AEDs after a first seizure, treatment of status epilepticus, and epilepsy in women.
• Evidence:
  • Newer AEDs: Ongoing research into new AEDs with novel mechanisms of action, improved tolerability, and efficacy for drug-resistant epilepsy. Examples include cenobamate, perampanel, lacosamide, brivaracetam.
  • Neurostimulation Devices: Expanding evidence for RNS, DBS, and VNS in improving seizure control and quality of life for carefully selected patients with drug-resistant epilepsy.
  • Genetic Discoveries: Advancements in genetic testing identifying new epilepsy genes and syndromes, guiding personalized treatment in some cases.
  • SUDEP Research: Increased understanding of SUDEP mechanisms and identification of potential biomarkers or preventative strategies.
• Controversies:
  • When to Initiate AEDs After a First Unprovoked Seizure: Remains a clinical debate, balancing recurrence risk against potential side effects of chronic medication. Current consensus favors individualized decision-making.
  • Optimal Management of Refractory Epilepsy: The timing and sequence of advanced therapies (surgery, neurostimulation, dietary therapies) in drug-resistant epilepsy are continually refined.
  • Long-term Cognitive Effects of AEDs: Ongoing research to better understand and mitigate the cognitive impact of various AEDs, especially in children and the elderly.

Key References

• Guidelines:
  • International League Against Epilepsy (ILAE): Official website and publications (e.g., Seizure Classification, Epilepsy Syndromes).
  • National Institute for Health and Care Excellence (NICE) Guidelines: Clinical guideline [CG137] on Epilepsy: diagnosis and management (UK).
  • American Academy of Neurology (AAN) Practice Guidelines: Various guidelines on epilepsy topics (e.g., treatment of convulsive status epilepticus in children and adults).
• Studies:
  • SANAD Study (Standard And New Antiepileptic Drugs): Landmark randomized controlled trials comparing efficacy and tolerability of various AEDs for focal and generalized epilepsies.
  • NEST Study (Neurological Emergencies Treatment Trials): Research on optimal acute management of status epilepticus (e.g., comparing different benzodiazepines and second-line AEDs).
  • MESS Trial (Medical versus Surgical treatment for Epilepsy in the elderly): Studies comparing different treatment strategies for older adults with epilepsy.
• Reviews:
  • UpToDate, Medscape, NEJM, Lancet Neurology: Comprehensive review articles and clinical updates on epilepsy and seizure management.
  • Epilepsia, Seizure, Journal of Clinical Neurophysiology: Specialized journals providing original research and review articles in epileptology.